|1.||Schwartz, Gary K: 4 articles (04/2013 - 03/2009)|
|2.||Odedra, Rajesh: 3 articles (05/2009 - 06/2007)|
|3.||Wilkinson, Robert W: 3 articles (05/2009 - 06/2007)|
|4.||Matsumura, Satoshi: 2 articles (09/2015 - 01/2010)|
|5.||Aihara, Arihiro: 2 articles (09/2015 - 01/2010)|
|6.||Arii, Shigeki: 2 articles (09/2015 - 01/2010)|
|7.||Kudo, Atsushi: 2 articles (09/2015 - 01/2010)|
|8.||Tanaka, Shinji: 2 articles (09/2015 - 01/2010)|
|9.||Nakamura, Noriaki: 2 articles (09/2015 - 01/2010)|
|10.||Schellens, Jan H M: 2 articles (10/2013 - 08/2012)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/01/2011 - "Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia."
05/15/2009 - "AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo."
10/01/2011 - "A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia."
07/15/2013 - "Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia."
09/01/2012 - "Barasertib (AZD1152) is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML). "
08/01/2012 - "Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)."
10/01/2009 - "The aim of this study was to evaluate and to mechanistically explore scheduling effects of AZD1152 on tumor responses to IR, in three different settings: neoadjuvant (AZD1152 before IR), adjuvant (IR before AZD1152), or concomitant treatments (AZD1152 plus one single IR dose). "
01/01/2014 - "The use of AZD1152, a selective Aurora-B inhibitor, counteracted tumorigenic potential and radioresistance phenotype by highly increasing apoptotic mechanisms in all gynecological cancer cell lines used. "
01/01/2014 - "Exponentially growing human endometrial (Ishikawa), cervical (HeLa), cervical (CASKI) and vulva (SiHa) cancer cells were used in culture treated with either control or MEK/ERK inhibitor or AZD1152 before and after irradiation. "
03/01/2011 - "Preclinical evaluation of AZD1152 has been reported in several human cancer models. "
|4.||Hepatocellular Carcinoma (Hepatoma)
|5.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
|1.||aurora kinase (aurora A kinase)
|5.||Small Interfering RNA (siRNA)
|10.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|1.||Heterologous Transplantation (Xenotransplantation)